Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Veltassa for hyperkalemia

Oct. 22, 2015

Vitamin B12-PYY3-36 peptide conjugate reduces food intake in vivo

Oct. 22, 2015

Yabao Pharmaceutical licenses second diabetes candidate from Lilly

Oct. 22, 2015

Arisaph starts phase II trial of niacin analogue ARI-3037-MO in patients with NAFLD or NASH

Oct. 21, 2015

La Jolla Pharmaceutical starts phase I trial of hepcidin formulation LJPC-401

Oct. 20, 2015

Addyi launched in the U.S. for generalized hypoactive sexual desire disorder

Oct. 20, 2015

Kowa files for approval of pemafibrate in Japan

Oct. 20, 2015

Alnylam describes a more potent RNAi agent targeting transthyretin for treating amyloidosis

Oct. 20, 2015

FDA places partial clinical hold on beloranib

Oct. 19, 2015

FDA issues complete response letter for saxagliptin/dapagliflozin NDA

Oct. 16, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...